Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?

To the Editor To date, the CONVERT trial was one of the largest prospective studies evaluating radiation fractionation in limited-stage small cell lung cancer (SCLC).¹ The successful execution of the trial by Faivre-Finn et al¹ was a major accomplishment to be envied in the United States, where roughly half of patients with limited-stage SCLC do not even receive radiation as part of initial management.² Salem et al³ presented a secondary analysis of the CONVERT trial that demonstrated the prognostic value of TNM.